Building on a 14+ year relationship with Chase, the Chief Medical Officer of Checkmate Pharmaceuticals retained The Chase Group to identify a critical hire for his medical team. The Chase Group is pleased to announce the successful placement of their Vice President, Head of Medical Development. This experienced leader is board certified in medical oncology and radiation therapy with expertise in all phases of pharmaceutical and biologic drug development. The Vice President, Head of Medical Development will lead the development of the company’s promising pipeline in the field of CpG oligonucleotides to develop immunotherapies and new treatment options for patients with cancer. The company is energized from their recent announcement of their Initial Public Offering, the experienced team they continue to build with this critical addition, and the prospects for their drug to make a real difference for patients. Congratulations Checkmate on the successful appointment of your Head of Medical Development! The Chase Group never loses sight of the fact that our services can profoundly impact the future success of an organization and we are honored to be entrusted with such a crucial placement for Checkmate. To find out how The Chase Group can help you identify and secure high caliber leadership for your team, please contact moira@chasegroup.com.
The Chase Group Successfully Secures Vice President, Head of Medical Development for Checkmate Pharmaceuticals
Building on a 14+ year relationship with Chase, the Chief Medical Officer of Checkmate Pharmaceuticals retained The Chase Group to identify a critical hire for his medical team. The Chase Group is pleased to announce the successful placement of their Vice President, Head of Medical Development. This experienced leader is board certified in medical oncology and radiation therapy with expertise in all phases of pharmaceutical and biologic drug development. The Vice President, Head of Medical Development will lead the development of the company’s promising pipeline in the field of CpG oligonucleotides to develop immunotherapies and new treatment options for patients with cancer. The company is energized from their recent announcement of their Initial Public Offering, the experienced team they continue to build with this critical addition, and the prospects for their drug to make a real difference for patients. Congratulations Checkmate on the successful appointment of your Head of Medical Development! The Chase Group never loses sight of the fact that our services can profoundly impact the future success of an organization and we are honored to be entrusted with such a crucial placement for Checkmate. To find out how The Chase Group can help you identify and secure high caliber leadership for your team, please contact moira@chasegroup.com.
The Chase Group Secures Clinical Operations Leadership for Alexza Pharmaceuticals
The Chase Group, committed to executive recruitment in life sciences, is pleased to announce the completion of another search for Alexza Pharmaceuticals, successfully securing Mike…
Arcturus Therapeutics Secures Head of Drug Safety Through Continued Partnership with The Chase Group
The Chase Group’s track record for success continues with another executive placement secured for Arcturus Therapeutics. Entering a new stage in clinical development, Arcturus retained…
Leadership Team Grows at Biologics Consulting Through Partnership with The Chase Group
Biologics Consulting, currently experiencing a season of growth, retained The Chase to build out their leadership team. Tasked with identifying a Regulatory Project Management Lead,…-
The Chase Group Successfully Completes Search for Vice President, Research & Development at Alexza Pharmaceuticals
Alexza Pharmaceuticals stands at the crossroads of innovation and advanced technology with a platform that has the potential to address unmet medical needs in neuroscience…. -
The Chase Group Successfully Places David Geller, MD as Head of Pulmonary & Rare Disease Clinical Development for Arcturus Therapeutics
The Chase Group (TCG) is pleased to announce the successful recruitment of David Geller, MD as the Vice President, Pulmonary and Rare Diseases Clinical Development… 
Drug Safety Leadership Team Grows at Ionis Pharmaceuticals Through Continued Partnership with The Chase Group
Ionis Pharmaceuticals retained The Chase Group to identify and secure the next member of their drug safety leadership team to support a robust and continually…